The significance of nanoparticles in medicine and their potential application in asthma

Stephanie Tortorella, Tom C. Karagiannis

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

Abstract

In an attempt to diagnose and treat highly complex and often heterogeneous diseases, research aims to utilise the modifiable properties of nano-sized particles. Properties such as size, shape, charge, hydrophobicity, and surface chemistry may be altered in order to facilitate and promote targeted cellular uptake. Following the first FDA-approved nanotherapeutic in 1990, more than 40 have been marketed worldwide with multiple nano-based medicines currently in development. Despite promising results, translation from pre-clinical experimentation to a clinical setting has proven to be difficult. In theory, nanoparticles are designed to possess characteristics which address many of the challenges associated with current clinical practices, such as low toxicity, stability, biocompatibility, favourable distribution within target tissue, and beneficial pharmacokinetic profiles. However, the complexity in the identification of the ideal properties which result in such characteristics is inherent of any therapeutic research, especially one as novel and relatively progressive. The development of nanoparticles for localised and systemic delivery to the lung in the treatment of respiratory disease also shows great potential. Due to the highly efficient clearance mechanisms in the lung, the ability for therapeutics to successfully deposit in the respiratory tract is a major challenge. Yet a correlation between exposure to environmentally and occupationally derived ultrafine (nano-sized) particles and respiratory disease has been established. By confirming that ultrafine particles have the capacity to deposit in parts of the lower respiratory tract to elicit a response albeit toxic, such epidemiological studies provide rationale for the development of nano-based pulmonary therapeutics. Although there has been little effort in designing nanoparticle systems for the treatment of lung disease including asthma, current research involves the development of nanocarriers for clinically relevant asthma drugs and antigen (for immunotherapy). With this, continued advancements in the understanding of human disease including asthma, coupled with knowledge regarding interactions between nanoparticle and cell/tissue systems, are required and provide the platform for nano-based therapeutic and diagnostic research.

Original languageEnglish
Title of host publicationMolecular Mechanisms and Physiology of Disease
Subtitle of host publicationImplications for Epigenetics and Health
EditorsNilanjana  Maulik, Tom  Karagiannis
Place of PublicationNew York
PublisherSpringer
Pages247-275
Number of pages29
ISBN (Electronic)9781493907069
ISBN (Print)9781493907052
DOIs
Publication statusPublished - 1 Feb 2014
Externally publishedYes

Keywords

  • Asthma
  • Biomedical imaging
  • Diagnostics
  • Drug delivery
  • Nanomedicine
  • Nanoparticles
  • Respiratory diseases
  • Tissue regeneration

Cite this

Tortorella, S., & Karagiannis, T. C. (2014). The significance of nanoparticles in medicine and their potential application in asthma. In N. Maulik, & T. Karagiannis (Eds.), Molecular Mechanisms and Physiology of Disease: Implications for Epigenetics and Health (pp. 247-275). New York: Springer. https://doi.org/10.1007/978-1-4939-0706-9_10
Tortorella, Stephanie ; Karagiannis, Tom C. / The significance of nanoparticles in medicine and their potential application in asthma. Molecular Mechanisms and Physiology of Disease: Implications for Epigenetics and Health. editor / Nilanjana  Maulik ; Tom  Karagiannis . New York : Springer, 2014. pp. 247-275
@inbook{e3fb314b842c463694b31ba1b040e9b9,
title = "The significance of nanoparticles in medicine and their potential application in asthma",
abstract = "In an attempt to diagnose and treat highly complex and often heterogeneous diseases, research aims to utilise the modifiable properties of nano-sized particles. Properties such as size, shape, charge, hydrophobicity, and surface chemistry may be altered in order to facilitate and promote targeted cellular uptake. Following the first FDA-approved nanotherapeutic in 1990, more than 40 have been marketed worldwide with multiple nano-based medicines currently in development. Despite promising results, translation from pre-clinical experimentation to a clinical setting has proven to be difficult. In theory, nanoparticles are designed to possess characteristics which address many of the challenges associated with current clinical practices, such as low toxicity, stability, biocompatibility, favourable distribution within target tissue, and beneficial pharmacokinetic profiles. However, the complexity in the identification of the ideal properties which result in such characteristics is inherent of any therapeutic research, especially one as novel and relatively progressive. The development of nanoparticles for localised and systemic delivery to the lung in the treatment of respiratory disease also shows great potential. Due to the highly efficient clearance mechanisms in the lung, the ability for therapeutics to successfully deposit in the respiratory tract is a major challenge. Yet a correlation between exposure to environmentally and occupationally derived ultrafine (nano-sized) particles and respiratory disease has been established. By confirming that ultrafine particles have the capacity to deposit in parts of the lower respiratory tract to elicit a response albeit toxic, such epidemiological studies provide rationale for the development of nano-based pulmonary therapeutics. Although there has been little effort in designing nanoparticle systems for the treatment of lung disease including asthma, current research involves the development of nanocarriers for clinically relevant asthma drugs and antigen (for immunotherapy). With this, continued advancements in the understanding of human disease including asthma, coupled with knowledge regarding interactions between nanoparticle and cell/tissue systems, are required and provide the platform for nano-based therapeutic and diagnostic research.",
keywords = "Asthma, Biomedical imaging, Diagnostics, Drug delivery, Nanomedicine, Nanoparticles, Respiratory diseases, Tissue regeneration",
author = "Stephanie Tortorella and Karagiannis, {Tom C.}",
year = "2014",
month = "2",
day = "1",
doi = "10.1007/978-1-4939-0706-9_10",
language = "English",
isbn = "9781493907052",
pages = "247--275",
editor = "Nilanjana  Maulik and {Karagiannis }, Tom ",
booktitle = "Molecular Mechanisms and Physiology of Disease",
publisher = "Springer",

}

Tortorella, S & Karagiannis, TC 2014, The significance of nanoparticles in medicine and their potential application in asthma. in N Maulik & T Karagiannis (eds), Molecular Mechanisms and Physiology of Disease: Implications for Epigenetics and Health. Springer, New York, pp. 247-275. https://doi.org/10.1007/978-1-4939-0706-9_10

The significance of nanoparticles in medicine and their potential application in asthma. / Tortorella, Stephanie; Karagiannis, Tom C.

Molecular Mechanisms and Physiology of Disease: Implications for Epigenetics and Health. ed. / Nilanjana  Maulik; Tom  Karagiannis . New York : Springer, 2014. p. 247-275.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

TY - CHAP

T1 - The significance of nanoparticles in medicine and their potential application in asthma

AU - Tortorella, Stephanie

AU - Karagiannis, Tom C.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - In an attempt to diagnose and treat highly complex and often heterogeneous diseases, research aims to utilise the modifiable properties of nano-sized particles. Properties such as size, shape, charge, hydrophobicity, and surface chemistry may be altered in order to facilitate and promote targeted cellular uptake. Following the first FDA-approved nanotherapeutic in 1990, more than 40 have been marketed worldwide with multiple nano-based medicines currently in development. Despite promising results, translation from pre-clinical experimentation to a clinical setting has proven to be difficult. In theory, nanoparticles are designed to possess characteristics which address many of the challenges associated with current clinical practices, such as low toxicity, stability, biocompatibility, favourable distribution within target tissue, and beneficial pharmacokinetic profiles. However, the complexity in the identification of the ideal properties which result in such characteristics is inherent of any therapeutic research, especially one as novel and relatively progressive. The development of nanoparticles for localised and systemic delivery to the lung in the treatment of respiratory disease also shows great potential. Due to the highly efficient clearance mechanisms in the lung, the ability for therapeutics to successfully deposit in the respiratory tract is a major challenge. Yet a correlation between exposure to environmentally and occupationally derived ultrafine (nano-sized) particles and respiratory disease has been established. By confirming that ultrafine particles have the capacity to deposit in parts of the lower respiratory tract to elicit a response albeit toxic, such epidemiological studies provide rationale for the development of nano-based pulmonary therapeutics. Although there has been little effort in designing nanoparticle systems for the treatment of lung disease including asthma, current research involves the development of nanocarriers for clinically relevant asthma drugs and antigen (for immunotherapy). With this, continued advancements in the understanding of human disease including asthma, coupled with knowledge regarding interactions between nanoparticle and cell/tissue systems, are required and provide the platform for nano-based therapeutic and diagnostic research.

AB - In an attempt to diagnose and treat highly complex and often heterogeneous diseases, research aims to utilise the modifiable properties of nano-sized particles. Properties such as size, shape, charge, hydrophobicity, and surface chemistry may be altered in order to facilitate and promote targeted cellular uptake. Following the first FDA-approved nanotherapeutic in 1990, more than 40 have been marketed worldwide with multiple nano-based medicines currently in development. Despite promising results, translation from pre-clinical experimentation to a clinical setting has proven to be difficult. In theory, nanoparticles are designed to possess characteristics which address many of the challenges associated with current clinical practices, such as low toxicity, stability, biocompatibility, favourable distribution within target tissue, and beneficial pharmacokinetic profiles. However, the complexity in the identification of the ideal properties which result in such characteristics is inherent of any therapeutic research, especially one as novel and relatively progressive. The development of nanoparticles for localised and systemic delivery to the lung in the treatment of respiratory disease also shows great potential. Due to the highly efficient clearance mechanisms in the lung, the ability for therapeutics to successfully deposit in the respiratory tract is a major challenge. Yet a correlation between exposure to environmentally and occupationally derived ultrafine (nano-sized) particles and respiratory disease has been established. By confirming that ultrafine particles have the capacity to deposit in parts of the lower respiratory tract to elicit a response albeit toxic, such epidemiological studies provide rationale for the development of nano-based pulmonary therapeutics. Although there has been little effort in designing nanoparticle systems for the treatment of lung disease including asthma, current research involves the development of nanocarriers for clinically relevant asthma drugs and antigen (for immunotherapy). With this, continued advancements in the understanding of human disease including asthma, coupled with knowledge regarding interactions between nanoparticle and cell/tissue systems, are required and provide the platform for nano-based therapeutic and diagnostic research.

KW - Asthma

KW - Biomedical imaging

KW - Diagnostics

KW - Drug delivery

KW - Nanomedicine

KW - Nanoparticles

KW - Respiratory diseases

KW - Tissue regeneration

UR - http://www.scopus.com/inward/record.url?scp=84929870157&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-0706-9_10

DO - 10.1007/978-1-4939-0706-9_10

M3 - Chapter (Book)

SN - 9781493907052

SP - 247

EP - 275

BT - Molecular Mechanisms and Physiology of Disease

A2 - Maulik, Nilanjana 

A2 - Karagiannis , Tom 

PB - Springer

CY - New York

ER -

Tortorella S, Karagiannis TC. The significance of nanoparticles in medicine and their potential application in asthma. In Maulik N, Karagiannis T, editors, Molecular Mechanisms and Physiology of Disease: Implications for Epigenetics and Health. New York: Springer. 2014. p. 247-275 https://doi.org/10.1007/978-1-4939-0706-9_10